MODERN APPROACHES TO PATHOGENETIC THERAPY OF ALLERGIC RHINITIS
Allergic rhinitis/rhinoconjunctivitis - IgE-mediated inflammation of the nasal mucosa, arising after contact with a causal allergen and manifested by rhinorrhea, nasal congestion, sneezing, lacrimation, etc. After exposure to the allergen, histamine, tryptase, cysteinyl leukotrienes are released from the cells of the mucous membrane of the cavity nose during the early and late phases of an allergic reaction. Insufficient clinical efficacy of antihistamines in allergic rhinitis, which block the acute histamine-dependent stage of allergic inflammation, is explained by the lack of effect on leukotrienes. This condition presupposes the development of a new strategy of rational pathogenetic therapy of allergic rhinitis, the use of leukotriene receptor inhibitors in combination with antihistamines. The article examines the effectiveness of the combination therapy Montral ML (levocetirizin 5 mg + montelukast 10 mg) in comparison with monotherapy levocetirizin 5 mg in allergic rhinitis caused by sensitization to allergens of Asteraceae pollen. It was shown sufficient control of the disease, positive results of treatment with combination therapy in comparison with monotherapy (p < 0.05). Possible areas of application Montral ML (levocetirizin 5 mg + montelukast 10 mg): treatment of symptoms of perennial (persistent) and seasonal (intermittent) allergic rhinitis.